{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-239246","form_type":"8-K","ticker":"VRDN","cik":"0001590750","company_name":"Viridian Therapeutics, Inc.\\DE","filed_at":"2026-05-26T20:05:16+00:00","discovered_at":"2026-05-26T20:07:00.525074+00:00","generated_at":"2026-05-26T20:50:39.516726+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"confidence":"high","headline":"Viridian inks commercial manufacturing deal with WuXi Biologics for veligrotug","bullets":["Agreement covers long-term supply of veligrotug drug substance and drug product, if approved.","WuXi Biologics is non-exclusive supplier; Viridian may use alternate manufacturers.","Initial term of 5 years, auto-renewing for successive 5-year periods unless 24-month non-renewal notice given.","Volume-based pricing fixed through Dec 31, 2026, then annually adjustable; pass-through costs reimbursed.","Company may terminate on 30 days' notice for change in law materially impacting WuXi's performance."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-239246","json":"https://secwatch.observer/filing/0001193125-26-239246.json","markdown":"https://secwatch.observer/filing/0001193125-26-239246.md","text":"https://secwatch.observer/filing/0001193125-26-239246.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590750/000119312526239246/0001193125-26-239246-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590750/000119312526239246/d111034d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T20:50:39.516726+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}